Relationship between body surface area and ALT normalization after long-term lamivudine treatment

Makoto Nakamuta, Shusuke Morizono, Yuichi Tanabe, Eije Kajiwara, Junya Shimono, Akihide Masumoto, Toshihiro Maruyama, Norihiro Furusyo, Hideyuki Nomura, Hironori Sakai, Kazuhiro Takahashi, Koichi Azuma, Shinji Shimoda, Kazuhiro Kotoh, Munechika Enjoji, Jun Hayashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation. Methods: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249), two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA, as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT, albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: For 1-year treatment, multivariate analysis revealed that BSA (P = 0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBV-DNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA (P = 0.0147) was the only factor for the biological effect, and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels. Conclusion: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA.

Original languageEnglish
Pages (from-to)6948-6953
Number of pages6
JournalWorld Journal of Gastroenterology
Volume11
Issue number44
DOIs
Publication statusPublished - Nov 28 2005

Fingerprint

Lamivudine
Body Surface Area
Hepatitis B e Antigens
Multivariate Analysis
Biological Factors
DNA
Therapeutics
Chronic Hepatitis B
Platelet Count
Bilirubin
Albumins
Observation
Polymerase Chain Reaction
Serum

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Nakamuta, M., Morizono, S., Tanabe, Y., Kajiwara, E., Shimono, J., Masumoto, A., ... Hayashi, J. (2005). Relationship between body surface area and ALT normalization after long-term lamivudine treatment. World Journal of Gastroenterology, 11(44), 6948-6953. https://doi.org/10.3748/wjg.v11.i44.6948

Relationship between body surface area and ALT normalization after long-term lamivudine treatment. / Nakamuta, Makoto; Morizono, Shusuke; Tanabe, Yuichi; Kajiwara, Eije; Shimono, Junya; Masumoto, Akihide; Maruyama, Toshihiro; Furusyo, Norihiro; Nomura, Hideyuki; Sakai, Hironori; Takahashi, Kazuhiro; Azuma, Koichi; Shimoda, Shinji; Kotoh, Kazuhiro; Enjoji, Munechika; Hayashi, Jun.

In: World Journal of Gastroenterology, Vol. 11, No. 44, 28.11.2005, p. 6948-6953.

Research output: Contribution to journalArticle

Nakamuta, M, Morizono, S, Tanabe, Y, Kajiwara, E, Shimono, J, Masumoto, A, Maruyama, T, Furusyo, N, Nomura, H, Sakai, H, Takahashi, K, Azuma, K, Shimoda, S, Kotoh, K, Enjoji, M & Hayashi, J 2005, 'Relationship between body surface area and ALT normalization after long-term lamivudine treatment', World Journal of Gastroenterology, vol. 11, no. 44, pp. 6948-6953. https://doi.org/10.3748/wjg.v11.i44.6948
Nakamuta, Makoto ; Morizono, Shusuke ; Tanabe, Yuichi ; Kajiwara, Eije ; Shimono, Junya ; Masumoto, Akihide ; Maruyama, Toshihiro ; Furusyo, Norihiro ; Nomura, Hideyuki ; Sakai, Hironori ; Takahashi, Kazuhiro ; Azuma, Koichi ; Shimoda, Shinji ; Kotoh, Kazuhiro ; Enjoji, Munechika ; Hayashi, Jun. / Relationship between body surface area and ALT normalization after long-term lamivudine treatment. In: World Journal of Gastroenterology. 2005 ; Vol. 11, No. 44. pp. 6948-6953.
@article{00e944aec0eb419cb8e2e43755da3896,
title = "Relationship between body surface area and ALT normalization after long-term lamivudine treatment",
abstract = "Aim: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation. Methods: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249), two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA, as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT, albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: For 1-year treatment, multivariate analysis revealed that BSA (P = 0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBV-DNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA (P = 0.0147) was the only factor for the biological effect, and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels. Conclusion: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA.",
author = "Makoto Nakamuta and Shusuke Morizono and Yuichi Tanabe and Eije Kajiwara and Junya Shimono and Akihide Masumoto and Toshihiro Maruyama and Norihiro Furusyo and Hideyuki Nomura and Hironori Sakai and Kazuhiro Takahashi and Koichi Azuma and Shinji Shimoda and Kazuhiro Kotoh and Munechika Enjoji and Jun Hayashi",
year = "2005",
month = "11",
day = "28",
doi = "10.3748/wjg.v11.i44.6948",
language = "English",
volume = "11",
pages = "6948--6953",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "44",

}

TY - JOUR

T1 - Relationship between body surface area and ALT normalization after long-term lamivudine treatment

AU - Nakamuta, Makoto

AU - Morizono, Shusuke

AU - Tanabe, Yuichi

AU - Kajiwara, Eije

AU - Shimono, Junya

AU - Masumoto, Akihide

AU - Maruyama, Toshihiro

AU - Furusyo, Norihiro

AU - Nomura, Hideyuki

AU - Sakai, Hironori

AU - Takahashi, Kazuhiro

AU - Azuma, Koichi

AU - Shimoda, Shinji

AU - Kotoh, Kazuhiro

AU - Enjoji, Munechika

AU - Hayashi, Jun

PY - 2005/11/28

Y1 - 2005/11/28

N2 - Aim: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation. Methods: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249), two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA, as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT, albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: For 1-year treatment, multivariate analysis revealed that BSA (P = 0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBV-DNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA (P = 0.0147) was the only factor for the biological effect, and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels. Conclusion: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA.

AB - Aim: To further evaluate the relationship between BSA and the effects of lamivudine in a greater number of cases and over a longer period of observation than in our previous evaluation. Methods: We evaluated 249 patients with chronic hepatitis B. The effects of treatment for one year (n = 249), two years (n = 147), and three years (n = 72) were evaluated from the levels of serum ALT and HBV-DNA, as biological and virological effects (undetectable levels by PCR), respectively. Moreover, several variables that could influence the response to treatment, including ALT, albumin, bilirubin, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: For 1-year treatment, multivariate analysis revealed that BSA (P = 0.0002) was the only factor for the biological effect, and that ALT (P = 0.0017), HBV-DNA (P = 0.0004), and HBeAg (P = 0.0021) were independent factors for the virological effect. For 2-year treatment, multivariate analysis again showed that BSA (P = 0.0147) was the only factor for the biological effect, and that ALT (P = 0.0192) and HBeAg (P = 0.0428) were independent factors for the virological effect. For 3-year treatment, multivariate analysis, however, could not reveal BSA (P = 0.0730) as a factor for the normalization of ALT levels. Conclusion: BSA is a significant predictor for the normalizing the effect of lamivudine therapy on ALT for an initial 2-year period, suggesting that lamivudine dosage should be based on the individual BSA.

UR - http://www.scopus.com/inward/record.url?scp=31144464804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144464804&partnerID=8YFLogxK

U2 - 10.3748/wjg.v11.i44.6948

DO - 10.3748/wjg.v11.i44.6948

M3 - Article

VL - 11

SP - 6948

EP - 6953

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 44

ER -